Free Trial

Nektar Therapeutics (NKTR) Insider Trading & Ownership

Nektar Therapeutics logo
$1.04 +0.04 (+3.47%)
(As of 10:00 AM ET)

Nektar Therapeutics (NASDAQ:NKTR) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
3.71%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
4
Amount Of
Insider Selling
(Last 12 Months)
$236,980.50
Get NKTR Insider Trade Alerts

Want to know when executives and insiders are buying or selling Nektar Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

NKTR Insider Buying and Selling by Quarter

Nektar Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/19/2024Howard W RobinCEOSell16,278$1.01$16,440.78  
11/19/2024Jonathan ZalevskyInsiderSell7,785$1.01$7,862.85  
8/19/2024Howard W RobinCEOSell14,881$1.28$19,047.68  
8/19/2024Jonathan ZalevskyInsiderSell6,866$1.28$8,788.48  
6/14/2024Robert ChessDirectorSell19,500$1.20$23,400.00  
5/17/2024Howard W RobinCEOSell16,650$1.75$29,137.50  
5/17/2024Jonathan ZalevskyInsiderSell7,355$1.75$12,871.25  
5/10/2024Deep Track Capital, LpMajor ShareholderSell56,000$1.78$99,680.00  
2/20/2024Howard W RobinCEOSell20,033$0.68$13,622.44  
2/20/2024Jonathan ZalevskyInsiderSell9,014$0.68$6,129.52  
(Data available from 1/1/2013 forward)

NKTR Insider Trading Activity - Frequently Asked Questions

The list of insiders at Nektar Therapeutics includes Deep Track Capital, Lp, Gil M Labrucherie, Howard W Robin, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, Robert Chess, and Roy A Whitfield. Learn more on insiders at NKTR.

3.71% of Nektar Therapeutics stock is owned by insiders. Learn more on NKTR's insider holdings.

The following insiders have sold NKTR shares in the last 24 months: Deep Track Capital, Lp ($99,680.00), Howard W Robin ($177,151.49), Jillian B Thomsen ($30,801.00), Jonathan Zalevsky ($86,448.50), Myriam Curet ($3,007.71), Robert Chess ($23,400.00), and Roy A Whitfield ($17,100.00).

Insiders have sold a total of 338,483 Nektar Therapeutics shares in the last 24 months for a total of $437,588.70 sold.

Nektar Therapeutics Key Executives

  • Mr. Howard W. RobinMr. Howard W. Robin (Age 71)
    CEO, President & Director
    Compensation: $1.83M
    2 recent trades
  • Mr. Mark A. Wilson (Age 52)
    Senior VP, Chief Legal Officer & Secretary
    Compensation: $749.99k
  • Dr. Jonathan Zalevsky Ph.D. (Age 49)
    Chief Research & Development Officer
    Compensation: $1.25M
  • Ms. Sandra A. Gardiner (Age 58)
    Interim Chief Financial Officer
  • Vivian Wu
    Director of Investor Relations & Corporate Affairs
  • Mr. Robert Bacci
    Senior Vice President of Human Resources & Facilities Operations
  • Ms. Jennifer Ruddock
    Chief Business Officer
  • Dr. Mary Tagliaferri L.Ac. (Age 58)
    M.D., Chief Medical Officer


This page (NASDAQ:NKTR) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners